112 related articles for article (PubMed ID: 7485251)
1. Schizophrenia: gender, family risk, and plasma homovanillic acid.
Dávila R; Zumárraga M; González-Torres MA; Andía I; Zamalloa MI; Basterreche E; Guimón J; Friedhoff AJ
Am J Med Genet; 1995 Apr; 60(2):154-6. PubMed ID: 7485251
[TBL] [Abstract][Full Text] [Related]
2. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
[No Abstract] [Full Text] [Related]
3. Plasma catecholamine metabolites and early response to haloperidol.
Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
[TBL] [Abstract][Full Text] [Related]
4. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
5. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
[TBL] [Abstract][Full Text] [Related]
7. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
8. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
9. Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients.
Davidson M; Losonczy MF; Mohs RC; Powchick P; Freed LB; Kaminsky R; Davis KL
Psychopharmacol Bull; 1987; 23(3):407-10. PubMed ID: 3432512
[No Abstract] [Full Text] [Related]
10. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
Davidson M; Losonczy MF; Mohs RC; Lesser JC; Powchik P; Freed LB; Davis BM; Mykytyn VV; Davis KL
Neuropsychopharmacology; 1987 Dec; 1(1):17-23. PubMed ID: 3509064
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Davidson M; Kendler KS; Davis BM; Horvath TB; Mohs RC; Davis KL
Psychiatry Res; 1985 Oct; 16(2):95-9. PubMed ID: 3865258
[TBL] [Abstract][Full Text] [Related]
12. Plasma homovanillic acid as a predictor of response to neuroleptics.
Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
[TBL] [Abstract][Full Text] [Related]
13. Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement.
Nibuya M; Kanba S; Sekiya U; Suzuki E; Matsuo Y; Kinoshita N; Shintani F; Yagi G; Asai M
Biol Psychiatry; 1995 Jul; 38(1):50-6. PubMed ID: 7548472
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
Volavka J; Douyon R; Convit A; Czobor P; Cooper TB
Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388
[No Abstract] [Full Text] [Related]
15. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
[TBL] [Abstract][Full Text] [Related]
16. Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
Koshikawa H; Suzuki E; Kanba S; Nibuya M; Ishizuki T; Kohno H; Kinoshita N; Shintani F; Yagi G; Nakaki T
Yakubutsu Seishin Kodo; 1991 Feb; 11(1):79-81. PubMed ID: 1679276
[No Abstract] [Full Text] [Related]
17. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in plasma homovanillic acid in acute psychosis.
Bowers MB; Swigar ME; Jatlow PI
N Engl J Med; 1983 Apr; 308(14):845-6. PubMed ID: 6835278
[No Abstract] [Full Text] [Related]
19. Plasma homovanillic acid as a predictor of response to fluphenazine treatment.
Van Putten T; Marder SR; Aravagiri M; Chabert N; Mintz J
Psychopharmacol Bull; 1989; 25(1):89-91. PubMed ID: 2772121
[No Abstract] [Full Text] [Related]
20. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
